In future studies, we will establish a cell-derived xenograft tumor model using LR HCC cells transfected with shPFKFB4 to validate the contribution of PFKFB4 to lenvatinib resistance in vivo. This evidence concerns the gene PFKFB4 and hepatocellular carcinoma.